Application of CRISPR/Cas9 in Treating Hepatitis B Virus
Journal of Liver Cancer
;
: 111-116, 2017.
Artículo
en Inglés
| WPRIM
| ID: wpr-120522
ABSTRACT
The advent of oral antiviral agents has revolutionized hepatitis B treatment. It has led to decreased incidence and mortality related to hepatocellular carcinoma. However, although nucleos(t)ide analogs (NA) are fast and potent in inhibiting hepatitis B virus (HBV) polymerase and reverse transcriptase activity, complete cure of the virus is not possible. The complete eradication of HBV requires the covalently-closed-circular DNA (cccDNA) to be eliminated. Novel gene editing methods, such as zing finger nucleases, transcription activator-like effector nucleases, and the clustered regularly interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) system, designed to target specific DNA sequences has great potential for therapeutic application. Among these, the CRISPR/Cas9 system may be the most feasible approach to eradicate HBV cccDNA. Further studies are needed to develop a more efficient and safer method of delivery using the CRISPR/Cas9 system to achieve complete cure of chronic hepatitis B.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
ADN
/
ADN Circular
/
Secuencia de Bases
/
Virus de la Hepatitis B
/
Incidencia
/
Mortalidad
/
ADN Polimerasa Dirigida por ARN
/
Carcinoma Hepatocelular
/
Hepatitis B Crónica
Tipo de estudio:
Estudio de incidencia
/
Estudio pronóstico
Idioma:
Inglés
Revista:
Journal of Liver Cancer
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS